# AMIODARONE (*Cordarone X*) (C) (Revised: December 2013)



TYPE:	Potent anti-arrhythmic agent [S4]		
PRESENTATION:	150mg in 3ml – glass ampoule		
ACTIONS:	Complex electrophysiological and pharmacological profile:		
	Prolongs the action potential duration; increases the refractoriness of all cardiac tissues		
	2. Blocks Na <sup>+</sup> channels (class I action)		
	3. Has some anti-adrenergic effects (class II action)		
	4. Ca <sup>2+</sup> blockade (class IV action)		
	5. Prolongs QT interval – reflects global prolongation of repolarisation		
	6. When given IV, there is a significant effect on the AV node which causes a delay in nodal conduction		
	7. Also effective for accessory pathway conduction		
USES:	Effective for both supraventricular and ventricular arrhythmias. ACTAS uses:		
	ICP	1. To slow the ventricular rate in atrial fibrillation and flutter	
	ICP	2. To treat VF and VT	
ADVERSE EFFECTS:	When given IV, can cause vasodilation, negative inotropic effects and hypotension (dose and rate dependent).		
	Occasionally may cause:		
	1. Bradycardia (especially in older patients)		
	2. Phlebitis		
	3. Hot flushes / sweating		
CONTRA- INDICATIONS:	<ol> <li>Known hypersensitivity</li> <li>Cross sensitivity to iodine</li> </ol>		

continues over

## AMIODARONE (C) – cont.



#### **DOSES:**

VF / V	T CARDIAC	<b>ARREST</b>
--------	-----------	---------------

#### ADULT:

**ICP** 

300mg IV/IO – over 30-60 seconds

#### PAEDIATRIC:

**ICP** 

5mg/kg IV/IO (to maximum 300mg) – over 30-60 seconds

### **VT, AF & A.FLUTTER – WITH CARDIAC OUTPUT**

#### ADULT:

**ICP** 

150mg IV via Springfusor (made up to 7ml total volume with normal saline; 7ml will run over 10 minutes)

(VT – if *extremely* compromised, may be given over 5 minutes by slow IV injection)

No repeat dose for either treatment regime.

#### PAEDIATRIC:

**ICP** 

5mg/kg IV (to maximum 150mg) via Springfusor (made up to 7ml total volume with normal saline; 7ml will run over 10 minutes)

(VT – if *extremely* compromised, may be given over 5 minutes by slow IV injection)

No repeat dose for either treatment regime.

#### **SPECIAL NOTE:**

Significant potential drug interactions.

The following may potentiate the actions of amiodarone:

- digoxin
- phenytoin (*Dilantin*)
- β blockers
- Ca<sup>2+</sup> channel blocker
- other antiarrhythmics